APA (7th ed.) Citation

Reifsnider, O., Hall, F., Sorensen, S., Proskorovsky, I., Girod, I., & Lee, J. (2017). Comment on: “Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal”. PharmacoEconomics, 35(6), 661-663. https://doi.org/10.1007/s40273-017-0502-8

Chicago Style (17th ed.) Citation

Reifsnider, Odette, Fiona Hall, Sonja Sorensen, Irina Proskorovsky, Isabelle Girod, and Jennifer Lee. "Comment on: “Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal”." PharmacoEconomics 35, no. 6 (2017): 661-663. https://doi.org/10.1007/s40273-017-0502-8.

MLA (9th ed.) Citation

Reifsnider, Odette, et al. "Comment on: “Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal”." PharmacoEconomics, vol. 35, no. 6, 2017, pp. 661-663, https://doi.org/10.1007/s40273-017-0502-8.